Zobrazeno 1 - 10
of 12
pro vyhledávání: '"W. Jeff Edenfield"'
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Mean paclitaxel plasma concentrations following nab-paclitaxel administration alone or with CC-486 in part 1 arm B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eefdbd5b10a450837b99a92154c80bc
https://doi.org/10.1158/1078-0432.22469373
https://doi.org/10.1158/1078-0432.22469373
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Table S1. CC-486 Plus Carboplatin Dose Levels in Part 1 Arm A Table S2. CC-486 Plus nab-Paclitaxel Dose Levels in Part 1 Arm B Table S3. CC-486 Dose Levels in Part 1 Arm C Table S4. Number of Patients With Treatment Emergent Adverse Events for Part 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91814ef9e8949aae1e95bacbfce8808a
https://doi.org/10.1158/1078-0432.22469364
https://doi.org/10.1158/1078-0432.22469364
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Mean total carboplatin plasma concentration following carboplatin administration alone or with CC-486 in part 1 arm A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::682bf5cb413b4e7a057f3bc39464dbea
https://doi.org/10.1158/1078-0432.22469376
https://doi.org/10.1158/1078-0432.22469376
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Pharmacodynamic Assessments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5a6bc2fae21e4f0b16b715a823c0ad
https://doi.org/10.1158/1078-0432.22469367.v1
https://doi.org/10.1158/1078-0432.22469367.v1
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Purpose: This large two-part, three-arm phase I study examined the safety and tolerability of CC-486 (an oral formulation of azacitidine, a hypomethylating agent) alone or in combination with the cytotoxic agents, carboplatin or nab-paclitaxel, in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fe263d5c1a31e04f57ce2ef635de4d3
https://doi.org/10.1158/1078-0432.c.6527238.v1
https://doi.org/10.1158/1078-0432.c.6527238.v1
Autor:
Aaron N. Nguyen, Johanna C. Bendell, Patricia LoRusso, Christophe Le Tourneau, Miguel Martin, Drew W. Rasco, W. Jeff Edenfield, Pamela N. Munster, Jose A. Lopez-Martin, Bert H. O'Neil, Gordon L. Bray, Elisabeth I. Heath, Eric Laille, Jorge DiMartino, Kejian Liu, Jan H.M. Schellens, Nicolas Isambert, Daniel D. Von Hoff, Ron H.J. Mathijssen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 17
Clinical Cancer Research, 24(17), 4072-4080. American Association for Cancer Research Inc.
Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2018, 24 (17), pp.4072-4080. ⟨10.1158/1078-0432.CCR-17-3716⟩
Clinical Cancer Research, 24(17), 4072-4080. American Association for Cancer Research Inc.
Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2018, 24 (17), pp.4072-4080. ⟨10.1158/1078-0432.CCR-17-3716⟩
Purpose: This large two-part, three-arm phase I study examined the safety and tolerability of CC-486 (an oral formulation of azacitidine, a hypomethylating agent) alone or in combination with the cytotoxic agents, carboplatin or nab-paclitaxel, in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cecb67cd7b46e1fc948f8af0c2ef502
https://escholarship.org/uc/item/95c380xz
https://escholarship.org/uc/item/95c380xz
Autor:
James L. Gulley, Kevin M. Chin, Ding Wang, Anja von Heydebreck, Hans Juergen Grote, David R. Spigel, Joseph Leach, Jason C. Chandler, Jean Marie Cuillerot, Deborah J.L. Wong, Nicholas Iannotti, W. Jeff Edenfield, Karen Kelly, Arun Rajan
Publikováno v:
The Lancet. Oncology, vol 18, iss 5
Gulley, JL; Rajan, A; Spigel, DR; Iannotti, N; Chandler, J; Wong, DJL; et al.(2017). Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. The Lancet Oncology, 18(5), 599-610. doi: 10.1016/S1470-2045(17)30240-1. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/4x88f141
Gulley, JL; Rajan, A; Spigel, DR; Iannotti, N; Chandler, J; Wong, DJL; et al.(2017). Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. The Lancet Oncology, 18(5), 599-610. doi: 10.1016/S1470-2045(17)30240-1. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/4x88f141
Summary Background Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in patients with advanced sol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af0b89f42adcf00035899d7aa93be9a3
https://escholarship.org/uc/item/4x88f141
https://escholarship.org/uc/item/4x88f141
Autor:
Milan Radovich, Curtis R. Pickering, Ina Felau, Gavin Ha, Hailei Zhang, Heejoon Jo, Katherine A. Hoadley, Pavana Anur, Jiexin Zhang, Mike McLellan, Reanne Bowlby, Thomas Matthew, Ludmila Danilova, Apurva M. Hegde, Jaegil Kim, Mark D.M. Leiserson, Geetika Sethi, Charles Lu, Michael Ryan, Xiaoping Su, Andrew D. Cherniack, Gordon Robertson, Rehan Akbani, Paul Spellman, John N. Weinstein, D. Neil Hayes, Ben Raphael, Tara Lichtenberg, Kristen Leraas, Jean Claude Zenklusen, Junya Fujimoto, Cristovam Scapulatempo-Neto, Andre L. Moreira, David Hwang, James Huang, Mirella Marino, Robert Korst, Giuseppe Giaccone, Yesim Gokmen-Polar, Sunil Badve, Arun Rajan, Philipp Ströbel, Nicolas Girard, Ming S. Tsao, Alexander Marx, Anne S. Tsao, Patrick J. Loehrer, Adrian Ally, Elizabeth L. Appelbaum, J. Todd Auman, Miruna Balasundaram, Saianand Balu, Madhusmita Behera, Rameen Beroukhim, Mario Berrios, Giovanni Blandino, Tom Bodenheimer, Moiz S. Bootwalla, Jay Bowen, Denise Brooks, Flavio M. Carcano, Rebecca Carlsen, Andre L. Carvalho, Patricia Castro, Lara Chalabreysse, Lynda Chin, Juok Cho, Gina Choe, Eric Chuah, Sudha Chudamani, Carrie Cibulskis, Leslie Cope, Matthew G. Cordes, Daniel Crain, Erin Curley, Timothy Defreitas, John A. Demchok, Frank Detterbeck, Noreen Dhalla, Hendrik Dienemann, W. Jeff Edenfield, Francesco Facciolo, Martin L. Ferguson, Scott Frazer, Catrina C. Fronick, Lucinda A. Fulton, Robert S. Fulton, Stacey B. Gabriel, Johanna Gardner, Julie M. Gastier-Foster, Nils Gehlenborg, Mark Gerken, Gad Getz, David I. Heiman, Shital Hobensack, Andrea Holbrook, Robert A. Holt, Alan P. Hoyle, Carolyn M. Hutter, Michael Ittmann, Stuart R. Jefferys, Corbin D. Jones, Steven J.M. Jones, Katayoon Kasaian, Patrick K. Kimes, Phillip H. Lai, Peter W. Laird, Michael S. Lawrence, Pei Lin, Jia Liu, Laxmi Lolla, Yiling Lu, Yussanne Ma, Dennis T. Maglinte, David Mallery, Elaine R. Mardis, Marco A. Marra, Julie Martin, Michael Mayo, Sam Meier, Michael Meister, Shaowu Meng, Matthew Meyerson, Piotr A. Mieczkowski, Christopher A. Miller, Gordon B. Mills, Richard A. Moore, Scott Morris, Lisle E. Mose, Thomas Muley, Andrew J. Mungall, Karen Mungall, Rashi Naresh, Yulia Newton, Michael S. Noble, Taofeek Owonikoko, Joel S. Parker, Joseph Paulaskis, Robert Penny, Charles M. Perou, Corinne Perrin, Todd Pihl, Amie Radenbaugh, Suresh Ramalingam, Nilsa Ramirez, Ralf Rieker, Jeffrey Roach, Sara Sadeghi, Gordon Saksena, Jacqueline E. Schein, Heather K. Schmidt, Steven E. Schumacher, Candace Shelton, Troy Shelton, Yan Shi, Juliann Shih, Gabriel Sica, Henrique C.S. Silveira, Janae V. Simons, Payal Sipahimalani, Tara Skelly, Heidi J. Sofia, Matthew G. Soloway, Joshua Stuart, Qiang Sun, Angela Tam, Donghui Tan, Roy Tarnuzzer, Nina Thiessen, David J. Van Den Berg, Mohammad A. Vasef, Umadevi Veluvolu, Doug Voet, Vonn Walter, Yunhu Wan, Zhining Wang, Arne Warth, Cleo-Aron Weis, Daniel J. Weisenberger, Matthew D. Wilkerson, Lisa Wise, Tina Wong, Hsin-Ta Wu, Ye Wu, Liming Yang, Jiashan Zhang, Erik Zmuda
Publikováno v:
Cancer Cell. 33:244-258.e10
Summary Thymic epithelial tumors (TETs) are one of the rarest adult malignancies. Among TETs, thymoma is the most predominant, characterized by a unique association with autoimmune diseases, followed by thymic carcinoma, which is less common but more
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e35f27925c5803045c599f387b8cd23
https://doi.org/10.1016/j.ccell.2018.01.003
https://doi.org/10.1016/j.ccell.2018.01.003
Publikováno v:
Clinical breast cancer. 17(1)
Introduction Metaplastic breast carcinoma (MBC) is a rare and aggressive histologic subtype of breast cancer comprising approximately 0.5% to 5.0% of all invasive breast cancers with a poor prognosis and limited therapeutic options. Patients and Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57d6e125def70258610bcf7b9032fca7
https://pubmed.ncbi.nlm.nih.gov/27568101
https://pubmed.ncbi.nlm.nih.gov/27568101
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.